Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | TDO2 | P48775 | 3/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.44 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2991689 | 0.98 | ACP3 (0.53) | ACP3ALDH1A1TSHRKIF11SLC6A2 | |
| SCHEMBL2009543 | 0.91 | KIF11 (0.46) | ACP3ALDH1A1TSHRKIF11IDO1 | |
| SCHEMBL28408423 | 0.87 | DPP4 (0.61) | ACP3ALDH1A1TSHRKIF11SLC6A2 | |
| SCHEMBL9116457 | 0.83 | ESR1 (0.43) | ACP3ALDH1A1TSHRSLC6A2SLC6A4 | |
| SCHEMBL3836311 | 0.82 | IDO1 (0.60) | ACP3ALDH1A1TSHRCACNA1CIDO1 | |
| SCHEMBL28312056 | 0.81 | KIF11 (0.59) | ACP3KIF11IDO1 | |
| SCHEMBL5540984 | 0.81 | PDE2A (0.46) | ACP3ALDH1A1KIF11 | |
| SCHEMBL11480062 | 0.81 | DPP4 (0.61) | TSHR | |
| SCHEMBL11478580 | 0.81 | DPP4 (0.61) | TSHR | |
| Hydrochloric Acid SCHEMBL11876965 | 0.80 | IDO1 (0.63) | ACP3ALDH1A1TSHRCACNA1CIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013085890-A1 | THERAPEUTIC METHODS | GLAXO GROUP LIMITED (GB) | 2013-06-13 | — | — | WO | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8350047-B2 | Methods of preparing secondary carbinamine compounds with boronic acids | THADANI AVINASH N (CA) | 2013-01-08 | — | — | US | disclosed |
| US-8350047-B2 | Methods of preparing secondary carbinamine compounds with boronic acids | THADANI AVINASH N (CA) | 2013-01-08 | — | — | US | disclosed |
| CN-101583615-B | Spiropiperidine glycinamide derivatives | HOFFMANN LA ROCHE | 2012-07-04 | — | — | CN | disclosed |
| EP-2104677-B1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-2104677-B1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-7964645-B2 | Glycine transporter gene 1 (GlyT-1); psychosis, schizophrenia, dementia; activation of NMDA receptors via GlyT-1 inhibition; N-(([(4-chloro-phenyl)-phenyl-methyl]-carbamoyl)-methyl)-4-fluorobenzamide for example | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | PANASONIC CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | US | disclosed |
| WO-2008084005-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084005-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | US | disclosed |
| WO-2008022938-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | ACP3 3681/4885ALDH1A1 292/4885TSHR 271/4885 |
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | AGXT, SLC1A2, GRIA1 | ACP3 4594/4885ALDH1A1 413/4885TSHR 1689/4885 |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | AVPR1A, AVPR2, AVPR1B | ACP3 4111/4885ALDH1A1 959/4885TSHR 186/4885 |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | ACP3 3681/4885ALDH1A1 292/4885TSHR 271/4885 |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | C9, BCAT2, SLC1A5 | ACP3 3450/4885ALDH1A1 636/4885TSHR 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.